Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
Megan M. Tu(University of Colorado Cancer Center), Dan Theodorescu(Cedars-Sinai Medical Center), Eric T. Clambey(University of Colorado Anschutz Medical Campus), Neeraj Agarwal(Louisiana State University Health Sciences Center New Orleans), Robert T. Jones(University of Colorado Anschutz Medical Campus), James C. Costello(University of Colorado Cancer Center), Alan J. Korman(Bristol-Myers Squibb (United States)), Terry L. Ng(Ottawa Hospital), Erin Michaud(Bristol-Myers Squibb (United States)), Jason E. Duex(University of Colorado Anschutz Medical Campus), Abigail K. Kimball(University of Colorado Anschutz Medical Campus), John C. Cambier(National Institutes of Health), Jun Yan(Bristol-Myers Squibb (United States)), Brianne M. Coleman(University of Colorado Denver), Elizabeth Saravia(Bristol-Myers Squibb (United States)), Linda K. Johnson, Hany Abdel-Hafiz(University of Arizona), Francis Y. F. Lee(Bristol-Myers Squibb (United States)), Andrii I. Rozhok(University of Colorado Denver), Han Chang(Bristol-Myers Squibb (United States)), Krista Menard(Bristol-Myers Squibb (United States)), Robert F. Graziano(Bristol-Myers Squibb (United States)), Ana Chauca-Diaz(University of Colorado Anschutz Medical Campus)
Cited by 126
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k